Skip to main content

Table 1 Characteristics of patients and samples used in microarray analysis

From: DCYTB is a predictor of outcome in breast cancer that functions via iron-independent mechanisms

Name

Number

Eventd (%)

Median recurrence-free survival (years)

Median follow-up (years)

Mean age, years (SD)

ER +/-

LN +/-

Her2

PR +/-

Grade 1/2/3

Normal tissue

Reference

Cohort #1a

741

167 (22)

7.8

8.7

60.8 (12.5)

643/89

364/358

NA

NA/NA

153/314/188

NA

Miller et al. [32]

Cohort #2b

869

251 (29)

4.3

4.5

51(11.1)

486/276

342/426

6

239/250

43/209/309

14c

 

GSE25055

303

63 (21)

2.4

2.6

50 (10.3)

170/133

217/86

4

140/157

19/113/149

NA

Hatzis et al. [40]

GSE25065

193

42 (22)

3.2

3.7

49.2 (10.6)

120/72

125/68

2

99/93

13/59/107

NA

Hatzis et al. [40]

GSE2034

272

100 (37)

7.2

8.6

54 (12)

196/76

0/272

NA

NA/NA

NA

NA

Wang et al. [73]

GSE42568

101

46 (46)

5.3

6.2

58.6 (11.6)

65/33

58/43

NA

NA/NA

11/37/53

14c

Clarke et al. [74]

  1. Complete datasets were not available for all patients. Discrepancies between total number of patients in cohorts and the number of patients evaluated based on individual characteristics (ER status, LN status, Her2, PR, grade) are due to missing data in each of these categories
  2. ER estrogen receptor, LN lymph node, Her2 human epidermal growth factor 2, PR progesterone receptor, NA not applicable
  3. aConstructed from data in caArray: mille-00271; GEO: GSE1456, GSE6532, GSE9195
  4. bConstructed from data in GEO: GSE25055, GSE25065, GSE2043, GSE42568
  5. cNormal tissue samples are not included in the number of patients (n)
  6. dCohort #1 events are DMFS (distant metastasis-free survival). All other cohorts are RFS (recurrence-free survival)